Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Rethinking the Gold Standard: Real-World Performance of the Serotonin Release Assay (SRA) and PF4-Dependent P-Selectin Expression Assay (PEA) in the Diagnosis of Heparin-Induced Thrombocytopenia (HIT)

Jackson Hoesley, Rance C Siniard, Laura J. Taylor, Cari Reed, Marisa B. Marques, Jori E. May

Blood (2022) 140 (Supplement 1): 1215–1216.

https://doi.org/10.1182/blood-2022-165647

Published: 2022

Journal Articles

A Road Paved with Good Intentions: A Platelet Count-Based Alert to Facilitate Diagnosis of Heparin-Induced Thrombocytopenia

Jori E. May, Kimberly D. Martin, Laura J. Taylor, Eric L. Wallace, Marisa B. Marques

Blood (2021) 138 (Supplement 1): 756.

https://doi.org/10.1182/blood-2021-145891

Published: 2021

Journal Articles

Thrombophilia Testing in Hospitalized Patients with Acute Ischemic Stroke: An Opportunity for Hematology Input

Jori May, MD, Chen Lin, MD, Kimberly Martin, PhD, Laura J Taylor, M.T., Radhika Gangaraju, MD

Blood (2019) 134 (Supplement_1): 2105.

https://doi.org/10.1182/blood-2019-122615

Published: 2019

Journal Articles

The Role of Thrombin Deficiency on Skeletal Health

Hillary J Taylor, BS, Galen Goldscheitter, BS, BA, Jason A Taylor, MD PhD

Blood (2018) 132 (Supplement 1): 5012.

https://doi.org/10.1182/blood-2018-99-118989

Published: 2018

Journal Articles

Metabolic strugGLS after FLT3 inhibition in AML

Samuel J. Taylor, Ulrich Steidl

Blood (2018) 131 (15): 1631–1632.

https://doi.org/10.1182/blood-2018-03-836338

Published: 2018

Journal Articles

PALB2 Mutational Status in Haematopoeitic Malignancies - a Potential Therapeutic Target?

Ceri Oldreive, PhD BSc, Tatjana Stankovic, MD PhD, Philip J Byrd, PhD, Grant S Stewart, PhD, Anna Smith, Alexander J Taylor, Peggy Fooks, Robert Horsley, James I Last, Dragana Janic, MD PhD, Lidija Dokmanovic, MD PhD, A. Malcolm R Taylor

Blood (2016) 128 (22): 2726.

https://doi.org/10.1182/blood.V128.22.2726.2726

Published: 2016

Journal Articles

The FLT3 Inhibitor Quizartinib Provides a Novel Strategy to Inhibit Chemotherapy-Induced Myelosuppression

Wallace Y Langdon, PhD, Samuel J Taylor, PhD, Johanna M Duyvestyn, BSc(Hons), Samantha A Dagger, BSc(Hons), George S. Vassiliou, MD PhD, Carolyn s. Grove, MD PhD

Blood (2016) 128 (22): 4041.

https://doi.org/10.1182/blood.V128.22.4041.4041

Published: 2016

Journal Articles

A Novel Role of PALB2 in Lymphoid Tumour Development

Tatjana Stankovic, MD PhD, Philip J Byrd, PhD, Grant S Stewart, PhD, Alexander J Taylor, Anna Smith, Peggy Fooks, Robert Horsley, James I Last, PhD, Dragana Janic, MD PhD, Lidija Dokmanovic, MD PhD, Antony W Oliver, PhD, A.Malcolm R Taylor, PhD

Blood (2016) 128 (22): 5113.

https://doi.org/10.1182/blood.V128.22.5113.5113

Published: 2016

Journal Articles

Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling

Samuel J. Taylor, Samantha A. Dagger, Christine B. F. Thien, Matthew E. Wikstrom, Wallace Y. Langdon

Blood (2012) 120 (19): 4049–4057.

https://doi.org/10.1182/blood-2012-06-436675

Published: 2012

Includes: Supplemental data

Journal Articles

FLT3 Inhibitor AC220 Is a Potent Therapy for Myeloproliferative Disease in c-Cbl RING Finger Mutant Mice

Wallace Y Langdon, PhD, Samantha A Dagger, Samuel J Taylor, Christine B F Thien, PhD, Matthew E Wikstrom, PhD

Blood (2011) 118 (21): 642.

https://doi.org/10.1182/blood.V118.21.642.642

Published: 2011

Journal Articles

An Economic Evaluation of Dasatinib for the Treatment of Imatinib-Resistant Patients with Chronic Myelogenous Leukaemia.

Matthew J Taylor, Ph.D., Ruth C Saxby, BA(Hons), Catherine Davis, PharmD

Blood (2009) 114 (22): 4535.

https://doi.org/10.1182/blood.V114.22.4535.4535

Published: 2009

Journal Articles

Human Embryonic Stem Cell-Derived CD34+ Cells Preferentially Develop into Endothelial Cells When Transplanted into Neonatal Immunodeficient Mice

Xinghui Tian, PhD, Melinda K. Hexum, Vesselin R. Penchev, Russell J. Taylor, Leonard Shultz, PhD, Dan S. Kaufman, MD, PhD

Blood (2008) 112 (11): 69.

https://doi.org/10.1182/blood.V112.11.69.69

Published: 2008

Journal Articles

Analysis of clonotypic switch junctions reveals multiple myeloma originates from a single class switch event with ongoing mutation in the isotype-switched progeny

Brian J. Taylor, Jitra Kriangkum, Julie A. Pittman, Michael J. Mant, Tony Reiman, Andrew R. Belch, Linda M. Pilarski

Blood (2008) 112 (5): 1894–1903.

https://doi.org/10.1182/blood-2008-01-129221

Published: 2008

Journal Articles

Genetic Variations in Genomic HAS1 Direct Aberrant Pre-mRNA Splicing That Generates the Prognostically Significant HAS1Vb Intronic Splice Variant.

Jitra Kriangkum, PhD, Anirban Ghosh, PhD, Brian J. Taylor, PhD, Linda M. Pilarski, PhD

Blood (2007) 110 (11): 2497.

https://doi.org/10.1182/blood.V110.11.2497.2497

Published: 2007

Journal Articles

Cost-Effectiveness Analysis in Canada of Dasatinib Versus Imatinib for the Treatment of Chronic Myelogenous Leukemia in Patients with Imatinib Resistance.

Jennifer C. Sambrook, M.Sc., Denise Zou, M.Sc., Matthew J. Taylor, Catherine C. Davis, Pharm.D., Alexandre Joyeux, PhD, Adrian R. Levy, Ph.D.

Blood (2007) 110 (11): 3328.

https://doi.org/10.1182/blood.V110.11.3328.3328

Published: 2007

Journal Articles

Molecular Characterization of Clonotypic VDJ Sequences in Waldenstrom’s Macroglobulinemia Suggests Independent Transformation Events in the Development of Biclonal B Cells.

Jitra Kriangkum, PhD, Brian J. Taylor, PhD, Steven P. Treon, MD, PhD, Michael J. Mant, MD, Tony Reiman, MD, Andrew R. Belch, MD, Linda M. Pilarski, PhD

Blood (2006) 108 (11): 4624.

https://doi.org/10.1182/blood.V108.11.4624.4624

Published: 2006

Journal Articles

Genomic Instability in Multiple Myeloma: Inducible Transfectants Provide a Model To Define the Role of RHAMM and Centrosome/Mitotic Spindle Stability in Myelomagenesis.

Brian J. Taylor, PhD, Eva Baigorri, MSc, Mary Hay, PhD, Tony Reiman, MD, Andrew R. Belch, MD, Linda M. Pilarski, PhD

Blood (2006) 108 (11): 5037.

https://doi.org/10.1182/blood.V108.11.5037.5037

Published: 2006

Journal Articles

Impaired class switch recombination (CSR) in Waldenström macroglobulinemia (WM) despite apparently normal CSR machinery

Jitra Kriangkum, Brian J. Taylor, Erin Strachan, Michael J. Mant, Tony Reiman, Andrew R. Belch, Linda M. Pilarski

Blood (2006) 107 (7): 2920–2927.

https://doi.org/10.1182/blood-2005-09-3613

Published: 2006

Journal Articles

Analysis of Clonotypic Switch Junctions Reveals Multiple Myeloma Originates from a Single Class Switch Event with Ongoing Mutation in the Isotype Switched Progeny.

Brian J. Taylor, PhD, Jitra Kriangkum, PhD, Jonathan J. Keats, PhD, Julie Pittman, BSc, Tony Reiman, MD, Andrew R. Belch, MD, Linda M. Pilarski, PhD

Blood (2005) 106 (11): 360.

https://doi.org/10.1182/blood.V106.11.360.360

Published: 2005

Journal Articles

Microfluidic Devices for Molecular Monitoring of Clonotypic IgH VDJ Signatures and the T(4;14) Translocation in Multiple Myeloma.

Linda M. Pilarski, PhD, Govindkrishna V. Kaigala, Jaron VanDjiken, Alexey Atrazhev, PhD, Brian J. Taylor, PhD, Andrew R. Belch, MD, Christopher J. Backhouse, PhD

Blood (2005) 106 (11): 1536.

https://doi.org/10.1182/blood.V106.11.1536.1536

Published: 2005

NARROW

Rethinking the Gold Standard: Real-World Performance of the Serotonin Release Assay (SRA) and PF4-Dependent P-Selectin Expression Assay (PEA) in the Diagnosis of Heparin-Induced Thrombocytopenia (HIT)

A Road Paved with Good Intentions: A Platelet Count-Based Alert to Facilitate Diagnosis of Heparin-Induced Thrombocytopenia

Thrombophilia Testing in Hospitalized Patients with Acute Ischemic Stroke: An Opportunity for Hematology Input

The Role of Thrombin Deficiency on Skeletal Health

Metabolic strugGLS after FLT3 inhibition in AML

PALB2 Mutational Status in Haematopoeitic Malignancies - a Potential Therapeutic Target?

The FLT3 Inhibitor Quizartinib Provides a Novel Strategy to Inhibit Chemotherapy-Induced Myelosuppression

A Novel Role of PALB2 in Lymphoid Tumour Development

Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling

FLT3 Inhibitor AC220 Is a Potent Therapy for Myeloproliferative Disease in c-Cbl RING Finger Mutant Mice

An Economic Evaluation of Dasatinib for the Treatment of Imatinib-Resistant Patients with Chronic Myelogenous Leukaemia.

Human Embryonic Stem Cell-Derived CD34+ Cells Preferentially Develop into Endothelial Cells When Transplanted into Neonatal Immunodeficient Mice

Analysis of clonotypic switch junctions reveals multiple myeloma originates from a single class switch event with ongoing mutation in the isotype-switched progeny

Genetic Variations in Genomic HAS1 Direct Aberrant Pre-mRNA Splicing That Generates the Prognostically Significant HAS1Vb Intronic Splice Variant.

Cost-Effectiveness Analysis in Canada of Dasatinib Versus Imatinib for the Treatment of Chronic Myelogenous Leukemia in Patients with Imatinib Resistance.

Molecular Characterization of Clonotypic VDJ Sequences in Waldenstrom’s Macroglobulinemia Suggests Independent Transformation Events in the Development of Biclonal B Cells.

Genomic Instability in Multiple Myeloma: Inducible Transfectants Provide a Model To Define the Role of RHAMM and Centrosome/Mitotic Spindle Stability in Myelomagenesis.

Impaired class switch recombination (CSR) in Waldenström macroglobulinemia (WM) despite apparently normal CSR machinery

Analysis of Clonotypic Switch Junctions Reveals Multiple Myeloma Originates from a Single Class Switch Event with Ongoing Mutation in the Isotype Switched Progeny.

Microfluidic Devices for Molecular Monitoring of Clonotypic IgH VDJ Signatures and the T(4;14) Translocation in Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only